X

Trial Profile

TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Women With High Risk and Premalignant Breast Conditions

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary)
Indications Breast disorders; Ductal lobular and medullary neoplasms; Hyperplasia
Focus Therapeutic Use
Acronyms TBCRC 042

Most Recent Events

09 May 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Dec 2024.
26 Feb 2019 Planned End Date changed from 1 Jan 2020 to 1 Jan 2025.
26 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com